198 related articles for article (PubMed ID: 34514929)
1. Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial.
Bertrand D; Stouten V; De Cock D; Pazmino S; Doumen M; de Wergifosse I; Joly J; Badot V; Corluy L; Hoffman I; Taelman V; De Knop K; Geens E; Langenaken C; Lenaerts JL; Lenaerts J; Walschot M; Mannaerts J; Westhovens R; Verschueren P
Scand J Rheumatol; 2022 Nov; 51(6):470-480. PubMed ID: 34514929
[TBL] [Abstract][Full Text] [Related]
2. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
3. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
4. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single-center study.
Yoshida S; Kotani T; Kimura Y; Matsumura Y; Yoshikawa A; Tokai N; Ozaki T; Nagai K; Takeuchi T; Makino S; Arawaka S
Int J Rheum Dis; 2019 Jan; 22(1):81-89. PubMed ID: 30168272
[TBL] [Abstract][Full Text] [Related]
6. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial.
Tascilar K; Hagen M; Kleyer A; Simon D; Reiser M; Hueber AJ; Manger B; Englbrecht M; Finzel S; Tony HP; Schuch F; Kleinert S; Wendler J; Ronneberger M; Figueiredo CP; Cobra JF; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Lorenz HM; Nuesslein H; Alten R; Kruger K; Henes J; Schett G; Rech J
Lancet Rheumatol; 2021 Nov; 3(11):e767-e777. PubMed ID: 38297524
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study.
Luis M; Pacheco-Tena C; Cazarín-Barrientos J; Lino-Pérez L; Goycochea MV; Vazquez-Mellado J; Burgos-Vargas R
Arthritis Rheum; 1999 Oct; 42(10):2160-5. PubMed ID: 10524688
[TBL] [Abstract][Full Text] [Related]
8. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.
Emery P; Horton S; Dumitru RB; Naraghi K; van der Heijde D; Wakefield RJ; Hensor EMA; Buch MH
Ann Rheum Dis; 2020 Apr; 79(4):464-471. PubMed ID: 31996367
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study.
Yamanaka H; Nagaoka S; Lee SK; Bae SC; Kasama T; Kobayashi H; Nishioka Y; Ueki Y; Seto Y; Nishinarita M; Tamura N; Kimura N; Saito K; Tomita T; Nawata Y; Suzuki S; Ishigatsubo Y; Munakata Y; Makino Y; Inoue E; Tanaka Y; Takeuchi T;
Mod Rheumatol; 2016 Sep; 26(5):651-61. PubMed ID: 26698929
[TBL] [Abstract][Full Text] [Related]
10. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
[TBL] [Abstract][Full Text] [Related]
11. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).
Fautrel B; Pham T; Alfaiate T; Gandjbakhch F; Foltz V; Morel J; Dernis E; Gaudin P; Brocq O; Solau-Gervais E; Berthelot JM; Balblanc JC; Mariette X; Tubach F
Ann Rheum Dis; 2016 Jan; 75(1):59-67. PubMed ID: 26103979
[TBL] [Abstract][Full Text] [Related]
12. Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission.
Curtis JR; Emery P; Karis E; Haraoui B; Bykerk V; Yen PK; Kricorian G; Chung JB
Arthritis Rheumatol; 2021 May; 73(5):759-768. PubMed ID: 33205906
[TBL] [Abstract][Full Text] [Related]
13. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
Ibrahim F; Lorente-Cánovas B; Doré CJ; Bosworth A; Ma MH; Galloway JB; Cope AP; Pande I; Walker D; Scott DL
Rheumatology (Oxford); 2017 Nov; 56(11):2004-2014. PubMed ID: 28968858
[TBL] [Abstract][Full Text] [Related]
14. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
Smolen JS; Pedersen R; Jones H; Mahgoub E; Marshall L
Rheumatology (Oxford); 2020 Jan; 59(1):153-164. PubMed ID: 31257453
[TBL] [Abstract][Full Text] [Related]
15. The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis.
Chen F; Lang Y; Geng S; Wang X; Lu L; Ye S; Zhang L; Li T
Clin Rheumatol; 2023 Oct; 42(10):2777-2786. PubMed ID: 37415053
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
[TBL] [Abstract][Full Text] [Related]
17. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial.
Ruwaard J; L' Ami MJ; Kneepkens EL; Krieckaert C; Nurmohamed MT; Hooijberg F; van Kuijk A; van Denderen JC; Burgemeister L; Rispens T; Boers M; Wolbink GJ
Scand J Rheumatol; 2023 Mar; 52(2):129-136. PubMed ID: 35234569
[TBL] [Abstract][Full Text] [Related]
18. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
19. Validation and predictive capacity of a Dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial.
Doumen M; Bertrand D; Pazmino S; De Cock D; Stouten V; Joly J; de Wergifosse I; Moeyersoons A; Westhovens R; Verschueren P
Clin Rheumatol; 2023 Jan; 42(1):39-45. PubMed ID: 35943667
[TBL] [Abstract][Full Text] [Related]
20. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
